WuXi AppTec

wuxiapptec.com

WuXi AppTec is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ABBVIE, GENOMICS MEDICINE IRELAND AND WUXI NEXTCODE ANNOUNCE LANDMARK POPULATION GENOMICS ALLIANCE

WuXi AppTec | January 09, 2017

news image

AbbVie (NYSE: ABBV), a global biopharmaceutical company, life-sciences startup Genomics Medicine Ireland Limited (GMI), and WuXi NextCODE, the global contract genomics organization, today announced the launch of a long-term strategic alliance to conduct population genomics research in Ireland aimed at advancing the discovery and development of novel therapeutic approaches to a range of serious diseases. The 15-year collaboration will focus on major chronic diseases within oncology, neuroscience ...

Read More

'NOVEL ANTI-IL-6 ANTIBODY FOR RHEUMATOID ARTHRITIS FROM WUXI–MEDIMMUNE JOINT VENTURE RECEIVES CLINICAL TRIAL PERMIT (CTP) FROM CFDA

WuXi AppTec | January 18, 2017

news image

WuXi AppTec, a global R&D enabling platform company, and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that an Investigational New Drug (IND) application for WBP216 (MEDI5117), a novel anti-IL-6 antibody for rheumatoid arthritis (RA) and other autoimmune disorders—developed by their joint venture, WuXi MedImmune—has been approved by the China Food and Drug Administration (CFDA) as a class I biologic to enter Phase 1 clinical trials in China....

Read More

WUXI APPTEC ACQUIRES BIOLOGY FOCUSED R&D SERVICE LEADER HD BIOSCIENCES

WuXi AppTec | January 20, 2017

news image

WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform, today announced that it has acquired HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO). After completion of acquisition, HD Biosciences will become a wholly-owned subsidiary of WuXi, and will continue to focus on growing its core competences and providing greater services. The acquisition will further strength...

Read More

WUXI APPTEC ELECTED BY IQVIA STEM CELL CENTER TO SERVE AS GMP MANUFACTURER OF ADVANCED THERAPIES

WuXi AppTec | November 17, 2017

news image

WuXi AppTec (WuXi), a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform company, announced that its Advanced Therapy Unit based in Philadelphia has been selected as a manufacturing partner for advanced therapies through the California Institute for Regenerative Medicine (CIRM) funded IQVIA (formerly QuintilesIMS) Stem Cell Center....

Read More
news image

ABBVIE, GENOMICS MEDICINE IRELAND AND WUXI NEXTCODE ANNOUNCE LANDMARK POPULATION GENOMICS ALLIANCE

WuXi AppTec | January 09, 2017

AbbVie (NYSE: ABBV), a global biopharmaceutical company, life-sciences startup Genomics Medicine Ireland Limited (GMI), and WuXi NextCODE, the global contract genomics organization, today announced the launch of a long-term strategic alliance to conduct population genomics research in Ireland aimed at advancing the discovery and development of novel therapeutic approaches to a range of serious diseases. The 15-year collaboration will focus on major chronic diseases within oncology, neuroscience ...

Read More
news image

'NOVEL ANTI-IL-6 ANTIBODY FOR RHEUMATOID ARTHRITIS FROM WUXI–MEDIMMUNE JOINT VENTURE RECEIVES CLINICAL TRIAL PERMIT (CTP) FROM CFDA

WuXi AppTec | January 18, 2017

WuXi AppTec, a global R&D enabling platform company, and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that an Investigational New Drug (IND) application for WBP216 (MEDI5117), a novel anti-IL-6 antibody for rheumatoid arthritis (RA) and other autoimmune disorders—developed by their joint venture, WuXi MedImmune—has been approved by the China Food and Drug Administration (CFDA) as a class I biologic to enter Phase 1 clinical trials in China....

Read More
news image

WUXI APPTEC ACQUIRES BIOLOGY FOCUSED R&D SERVICE LEADER HD BIOSCIENCES

WuXi AppTec | January 20, 2017

WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform, today announced that it has acquired HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO). After completion of acquisition, HD Biosciences will become a wholly-owned subsidiary of WuXi, and will continue to focus on growing its core competences and providing greater services. The acquisition will further strength...

Read More
news image

WUXI APPTEC ELECTED BY IQVIA STEM CELL CENTER TO SERVE AS GMP MANUFACTURER OF ADVANCED THERAPIES

WuXi AppTec | November 17, 2017

WuXi AppTec (WuXi), a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform company, announced that its Advanced Therapy Unit based in Philadelphia has been selected as a manufacturing partner for advanced therapies through the California Institute for Regenerative Medicine (CIRM) funded IQVIA (formerly QuintilesIMS) Stem Cell Center....

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us